EYPT News and Press, EyePoint Pharmaceuticals Inc. From 01/17/24

2024-01-17 06:00:39 ET More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal Countdown To Clarity: EyePoint's December Data Delivery EyePoint commences $175M stock offering to advance wet AMD therapy into...

2024-01-11 16:37:35 ET Gainers: Ventyx Biosciences ( VTYX ) +6% . EyePoint Pharmaceuticals ( EYPT ) +3% . HashiCorp ( HCP ) +3% . Nubia Brand International  ( NUBI ) +2% . Microvision ( MVIS ) +2% . Losers: Spectaire...

WATERTOWN, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase ...

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Execut...

WATERTOWN, Mass., Dec. 08, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritte...

2023-12-06 19:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-06 01:37:20 ET More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December D...

WATERTOWN, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 1...

2023-12-05 10:30:35 ET Summary EyePoint Pharmaceuticals, Inc. EYP-1901, a potential treatment for wet age-related macular degeneration, showed positive results in a Phase 2 study, meeting primary and secondary endpoints. The drug demonstrated non-inferiority to the current standar...

2023-12-05 07:55:14 ET EyePoint Pharmaceuticals (NASDAQ: EYPT) stock price has surged hard this week as it became a favorite among StockTwits traders. The shares jumped to a high of $22.40 on Monday, its highest point since November 2019. They have now risen by over 778% from the lowest...